Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Fluxion Biosciences Releases IsoFlux Rare Cell Enrichment Kit

Published: Tuesday, January 21, 2014
Last Updated: Tuesday, January 21, 2014
Bookmark and Share
New bead chemistry enables more options for targeted cell enrichment.

Fluxion Biosciences, Inc. has announced the release of a new reagent kit for the IsoFlux System designed to provide more options for circulating tumor cell (CTC) and other rare cell capture from biological samples.

The IsoFlux Rare Cell Enrichment (Streptavidin) Kit incorporates streptavidin-coated magnetic beads that can bind with one or more biotinylated antibodies targeted towards cell-surface markers on the cells of interest.

This new kit facilitates capture of targeted rare cell populations that can include: CTCs, cells undergoing epithelial to mesenchymal transition (EMT), cells expressing a particular drug or disease target, stem cells, and immune cells.

Similar to the existing IsoFlux enrichment kits, the IsoFlux Rare Cell Enrichment (Streptavidin) Kit utilizes an advanced microfluidic technology to achieve targeted, high sensitivity rare cell capture.

The cells collected with this kit are immediately ready for downstream analysis, including qPCR (gene expression, genotyping), next-generation sequencing (NGS), and immunofluorescence imaging. The samples are optimized for molecular analysis and feature high cell recovery, minimal background cells, and low-volume elution.

“The IsoFlux System has been adopted by labs across the world that continue to identify new applications,” said Michael Schwartz, Program Director. “Many of these new applications benefit from the well understood and utilized streptavidin-biotin chemistry. This new kit provides a simple, off-the-shelf reagent kit that can target a wide variety of cell types using familiar chemistry.”

The IsoFlux Rare Cell Enrichment (Streptavidin) Kit is available immediately.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Fluxion Receives $1.2M NIH Grant for the Development of Drug Discovery Platform
Grant funds development of multiplexed single-cell electroporation system for highly controlled siRNA delivery.
Monday, May 21, 2007
Scientific News
Stem Cells in Drug Discovery
Potential Source of Unlimited Human Test Cells, but Roadblocks Remain.
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
Defining Immortality of Stem Cells
Researchers defined the mechanisms underlying increased protein quality control of pluripotent stem cells.
Enhancing CRISPR to Explore Further
Researchers have developed sOPTiKO, a more efficient and controllable CRISPR genome editing platform.
Regenerating Diseased Hearts
Researchers from the University of Otago have probed the potential of adult stem cell types to repair diseased hearts.
Stem Cells Police Themselves to Reduce Scarring
Scientists have discovered stem cells in muscle fibers change gene expressions to respond to injury.
Bright Red Fluorescent Protein Created
Scientists have created a bright red, fluorescent protein that could be used to track essential cellular processes.
Protein Self-Regulates Abundance
Researchers have uncovered how a protein, that plays a crucial role in embryonic stem cell renewal, is regulated.
Topical Immunotherapy Effective Against Early Skin Cancer
Combination of two commonly used drugs triggers immune response against precancerous skin lesions.
Factors Behind Suppression of Stem Cell Mobilization Revealed
The findings could lead to improvements in transplantation therapy.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!